

FDA Blood Safety Requirements • PRT Implementation

Notification Date: 27 AUG 2020

Effective Date: 01 SEP 2020

Pathogen Reduction Technology - Platelets

The FDA increased its focus on blood safety, and in September 2019 released Final Guidance for mitigating bacterial contamination in platelet donations. The South Bend Medical Foundation (SBMF) will be implementing Cerus Intercept Pathogen Reduction Technology (PRT) to comply with this guidance beginning September 1, 2020. The product will be labeled as APHERESIS PLATELETS LEUKOREduced with new wording added to the label: PSORALEN-TREATED. The bag is 2.8 inches longer, however the platelet volume is the same. You will continue to receive the bacterial tested product during this transition.

The HCPCS code for this product is P9073

For more information on the Cerus system, please visit http://bit.ly/Cerus_Implementation

If you have any questions or concerns, please feel free to reach out to your Account Executive; Laura Balciunas, lbalciunas@sbmf.org or Meghan Berkheiser, mberkheiser@sbmf.org.

[SBMF online Test Directory](#)

Questions: Please contact **CLIENT SUPPORT SERVICES** at **800-950-7263**

Client Notices are distributed electronically.

Email addresses may be added/unsubscribed at our website: [Client Notices](#)

SOUTH BEND MEDICAL FOUNDATION

530 North Lafayette Boulevard • South Bend, Indiana 46601
(574) 234-4176 • (800) 544-0925 • www.sbmf.org
Joyce L. Simpson, M.D. • *Medical Director*